News & Resources

Published On 30 April

Onco-PDO cancer test successfully registered for CE Mark

Onco-PDO cancer test successfully registered for CE Mark

Learn more
Published On 11 December

The war against cancer will be fought better with improved decision making tools

Excerpt: The number of people living with cancer continues to grow around the world. The World Health Organisation predicts next year there will be 4.5 million new cancer cases and 6.7 million by 2040 – and that’s just in China. Globally there are 15 million today. “Cancer is affecting everybody – almost everyone knows someone […]

Learn more
Published On 21 October

Invitrocue Establishes Hong Kong Laboratory

Invitrocue Establishes Hong Kong Laboratory Innovative life sciences company Invitrocue Limited (ASX: IVQ) (‘Invitrocue’ or ‘the Company’) is pleased to announce the establishment of laboratory facility in Hong Kong. The Hong Kong facility, which will be used for research and development and for commercial purposes, provides Invitrocue with better access to the network of supportive […]

Learn more
Published On 21 October

Invitrocue Clinical Studies underway in Germany

Invitrocue Clinical Studies underway in Germany Innovative life sciences company Invitrocue Limited (ASX: IVQ) (‘Invitrocue’ or ‘the Company’) is pleased to announce that a clinical validation study is underway for its Onco-PDO test with Klinikum Rechts der Isar der Technischen Universitat Munchen, Comprehensive Cancer Center Munich, Germany.

Learn more
Published On 09 September

Collaboration with National University Hospital Singapore

Collaboration with National University Hospital Singapore 08 August, 2019: Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the commencement of a clinical validation collaboration with National University Hospital (NUH), a leading public teaching hospital in Singapore. The aim of the clinical study is to validate Invitrocue’s Onco-PDO drug screening […]

Learn more
Published On 06 May

Invitrocue Appoints Global Insurance Advisor

IVQ Appoints Global Insurance Advisor 06 May, 2019: Innovative life sciences company Invitrocue Limited (ASX: IVQ), (‘Invitrocue’ or ‘the Company’), is please to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor. In his role at Invitrocue, Dato Dr Wahab will advise and support the Company’s global insurance strategy for its Onco […]

Learn more
Published On 19 February

Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

EXCERPT:  February 18, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant. Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). She is an […]

Learn more
Published On 11 February

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

EXCERPT:  February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system […]

Learn more
Published On 23 January

IVQ technology development agreement with SIBCB on breast cancer.

EXCERPT: January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco-PDO® […]

Learn more
Published On 21 January

Invitrocue roll-out of Onco-PDO services in Germany

EXCERPT: “We are pleased to establish Invitrocue’s first laboratory in Europe, quickly expanding the availability of Onco-PDO® to a much wider patient and physician group. Approximately one quarter of the global total of cancer cases are in Europe with some 3.7 million new patients a year. Our collaboration with Systasy enables us to deliver against […]

Learn more